Nccn Announces Funding For Prostate Cancer Research Projects, In Collaboration With Pfizer And Astellas
Nccn Announces Funding For Prostate Cancer Research Projects, In Collaboration With Pfizer And Astellas
11/04/21, 8:35 AM
The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) today announced projects awarded to develop innovative and impactful studies that address unmet needs, as well as support the design and performance of enzalutamide research, in the treatment of prostate cancer. Grant funding will be provided by Pfizer Global Medical Grants (Pfizer) and Astellas Pharma Global Development (Astellas).
Company Info
Additional Info
The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 31 leading cancer centers devoted to patient care, research, and education, is dedicated to improving and facilitating quality, effective, efficient, and accessible cancer care so that patients can live better lives. NCCN offers a number of programs to give clinicians access to tools and knowledge that can help guide decision-making in the management of cancer.